The incidence and outcome of respiratory distress syndrome in preterm babies in relation to administration of antenatal corticosteroids by Abdul Jaleel, Shermin Nasreen et al.
Vol 5 | Issue 4 | Apr 2018 Indian J Child Health 267
Original Article
The incidence and outcome of respiratory distress syndrome in preterm babies 
in relation to administration of antenatal corticosteroids
Shermin Nasreen Abdul Jaleel1, Bindu Sarojum2, Bindusha Sasidharan2, Priya Gopala Krishnan3
From 1Assistant Professor, 2Associate Professor, 3Post Graduate Student, Department of Pediatrics, Government Medical College, 
Thiruvananthapuram, Kerala, India
Correspondence to: Bindu Sarojum, Sooryagayathri, TC18//605(3) Punnakkamugal, Asramom Road Aramada PO, PIN-695032 
MD paediatrics, Associate Professor, Department of Pediatrics, Government Medical College, Thiruvananthapuram, Kerala. 
E-mail: bindusarojam@gmail.com
Received - 05 March 2018 Initial Review - 30 March 2018 Published Online - 23 May 2018
The morbidity and mortality rates of premature infants are much higher than those of full-term babies. Premature infants have a higher incidence of respiratory distress 
syndrome (RDS), which is one of the main causes of early neonatal 
mortality. Corticosteroid consumption in pregnancy can stimulate 
the maturation of alveolar type 2 cells to produce surfactant 
and elicit architectural maturation of the fetal lung.[1] Therefore, 
antenatal corticosteroid (ACS) can reduce the incidence of RDS, 
perinatal and neonatal death, and severe morbidity in premature 
infants below 34 weeks gestation.[2-6] Corticosteroid administration 
before anticipated preterm birth is one of the most important 
antenatal therapies available to improve newborn outcomes.[7-12] 
The National Institute of Health[13] recommended the use of ACS 
among mothers with gestational age between 24 and 34 weeks to 
improve the outcome of preterm infants and in particular will reduce 
the incidence and severity of RDS. Recommendation of ACS 
treatment consists of two doses of 12 mg of betamethasone given 
intramuscularly 24 h apart or four doses of 6 mg of dexamethasone 
given intramuscularly 12 h apart. Several studies regarding repeated 
courses or weekly courses of ACS for preterm infants to enhance 
their lung maturation were reported. A Cochrane Database review 
published in 2006 summarized 21 studies including 3885 mothers 
and 4269 infants and confirmed significant reductions in the risks of 
mortality, RDS, and intraventricular haemorrhage among preterm 
infants by 31%, 44%, and 46%, respectively, after a single course of 
steroids[14,15] Although the effects of ACS on lung maturation appear 
to be dose dependent, the biological effects and optimal dosage 
regimen of antenatal glucocorticoids remain under investigation.
Although our hospital policy is to give two doses of 
betamethasone 24 h apart, some of the mothers delivered within 
24 h of the first dose of steroid. The babies of mothers who 
received a single dose of corticosteroid were included in the 
study as a separate group. It is a well-known fact that a single 
course (two doses) of ACS for the pregnant woman at risk of 
preterm delivery is the standard of care. There are many studies 
that compare the outcome between a single course and multiple 
courses of ACS. A single course of ACS is two doses of ACS 
24 h apart for mothers with imminent preterm birth. However, 
there are no studies that compare the outcome of preterm babies 
whose mothers received a single dose and those with two doses 
of betamethasone in a single course of antenatal steroid therapy. 
Hence, the present study was conducted with an aim to measure 
the incidence of RDS and its outcome in preterm babies of 
<34 weeks of gestation born to mothers who had received ACS 
and to compare the outcome between a single-dose ACS and 
double-dose ACS groups.
ABSTRACT
Background: Premature infants have a higher incidence of respiratory distress syndrome (RDS), which is one of the main causes 
of early neonatal mortality. Objectives: The objective is to study the incidence and outcome of RDS in preterm babies <34 weeks 
of gestation born to mothers who had received antenatal corticosteroids (ACS). Methodology: A prospective observational study 
was conducted among preterm babies from January 2015 to December 2015 in a tertiary care hospital of South India. Details of 
the mothers with a period of gestation 34 weeks or less who had received ACS were recorded. Results: The study population 
included 749 preterm babies (<34 weeks) delivered in our hospital. Among them, 698 (93.2%) mothers received two doses of ACS 
and 51 (6.8%) received only a single dose of ACS. Neonates whose mothers received two doses of ACS had a significantly lower 
incidence of RDS (27.6% vs. 100%, p<0.001), lower rate of mechanical ventilation (45% vs. 72.5%, p<0.001), and higher survival 
rate (87% vs. 68.6%, p=0.001) than neonates whose mothers received a single dose of ACS. The occurrence of RDS is highest in 
26–28 weeks babies (60%) and least in 28–32 weeks babies (32%). Conclusion: A single complete course of ACS (two doses 24 h 
apart) is efficacious than one dose of ACS with respect to prevention of RDS, neonatal mortality, and need for mechanical ventilation.
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METHODOLOGY
We undertook a prospective observational study in a tertiary care 
teaching hospital in Kerala, South India. The study was approved 
by the institutional ethical committee. Informed written consent was 
obtained from parents of all subjects before enrolment in the study.
All preterm babies of <34 weeks gestational age born to 
mothers who had received ACS (single dose or two doses) in our 
hospital during the period January 2015–December 2015 were 
included in the study. The babies with major structural anomalies, 
chromosomal abnormalities, and steroid use for other indications 
were excluded from the study. Based on the past 12 months 
admission rate in our hospital, with requisite inclusion and 
exclusion criteria, a convenient sample size of 749 consecutive 
preterm newborns and their mothers were included in the study.
Details of the mothers with a period of gestation 34 weeks 
or less who had received ACS were collected from the place of 
delivery (labor room or operation theater). Those who received 
two doses of ACS and those who delivered within 24 h of the 
first dose were followed up, and their newborns were monitored 
for the probable occurrence of RDS. Infants were divided into 
one-dose ACS group and two-dose ACS group to evaluate the 
different outcome between these two groups. The outcome was 
measured as the proportion of babies who developed RDS. RDS 
was defined as onset of respiratory distress within 6 hours of birth 
in a preterm baby (<34 weeks) with chest X-ray showing poor 
expansion, air bronchogram, or reticulogranular pattern.
These newborns were classified based on their gestational age 
into three groups as 26–28 weeks, 28–32 weeks, and 32–34 weeks. 
The incidence of RDS, the requirement of continuous positive 
airway pressure (CPAP), mechanical ventilation, and need for 
surfactant were compared between the groups. The neonatal 
outcome including survival rate, the need for surfactant treatment, 
requirement of CPAP, and mechanical ventilation was also analyzed 
and compared between the one-dose and two-dose ACS groups.
Data were analyzed using the Statistical Package for the Social 
Sciences software version 22.0 (SPSS, IBM Inc., New York). 
Baseline variables were described by descriptive statistics, and 
dichotomous variables were compared by Chi-square test. The 
p<0.05 was considered statistically significant.
RESULTS
The study included 749 preterm newborns (<34 weeks) of 9320 
deliveries that occurred in the year 2015 in our hospital.
The mothers of all these 749 preterm babies received 
corticosteroid during their antenatal period. Among 749 mothers, 
698 (93.2%) received two doses of antenatal steroid, and of 749 
preterm babies, 244 (32.6%) developed RDS. All babies required 
oxygen support, among which 120 (49.2%) babies received CPAP 
and 124 (50.8%) required mechanical ventilation. Our unit did not 
practice rescue surfactant administration. Hence, the surfactant 
was administered only to babies who have a Downe’s score of 
more than 4. A total of 72.5% babies with RDS required surfactant, 
of which 76.8% survived. Among babies who received two doses 
of antenatal steroids, 137 (70%) required surfactant therapy 
and 56 (30%) babies improved without surfactant therapy. The 
survival rate among babies with RDS was 83.2% (203) (Table 1).
Gestational age-wise distribution (Table 2) showed that 83.7% 
of babies were from 28 to 32 weeks group. The incidence of RDS 
Table 2: Gestational age‑wise distribution of preterm newborns
Gestational age 26–28 weeks n=5 28–32 weeks n=627 32–34 weeks n=117 Total
Received ACS (2) 3 (0.4) 582 (83) 113 (16) 698
Received ACS (1) 2 (3.9) 45 (88.2) 4 (7.8) 51
RDS 3 (60) 201 (32) 40 (34) 244
Oxygen support 3 (100) 201 (100) 40 (100) 244
CPAP 0 (0) 98 (49) 22 (55) 120
Mechanical ventilation 3 (100) 103 (51) 6 (15) 124
Surfactant 3 (100) 163 (81) 11 (27.5) 177
RDS: Respiratory distress syndrome, ACS: Antenatal corticosteroids, CPAP: Continuous positive airway pressure
Table 1: Baseline characteristics of preterm babies and mothers
Mother and Baby details Total (%) One dose ACS (%) Two dose ACS (%)
Mothers received ACS and delivered preterm 749 51 (6.8) 698 (93.2)
Preterm babies developed RDS 244 (32.6) 51 (20.9) 193 (79.1)
Babies with RDS needed CPAP support 120 (49.2) 14 (11.6) 106 (88.4)
Babies with RDS needed mechanical ventilation 124 (50.8) 37 (29.8) 87 (70.2)
Babies with RDS received surfactant 177 (72.5) 40 (22.59) 137 (77.4)
Babies with RDS not received surfactant 67 (27.45) 11 (16.4) 56 (83.58)
Details of Babies with RDS Total Died Survived
Pre term babies developed RDS 244 (32.6) 41 (16.8) 203 (83.2)
Preterm babies with RDS received surfactant 177 (72.5) 41 (23.16) 136 (76.83)
RDS: Respiratory distress syndrome, ACS: Antenatal corticosteroids, CPAP: Continuous positive airway pressure
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was more in babies <28 weeks (60%) than in the 32–34 weeks 
group (34%) and 28–32 weeks group (32%). The data showed 
that 28–32 weeks group was benefitted the most from antenatal 
steroids.
Among the babies, who developed RDS, the need for CPAP 
and mechanical ventilation was higher for preterm babies born 
to mothers who received a single dose of corticosteroids than 
preterm born to mothers who received two doses of antenatal 
steroids (Table 3).
The difference between babies of mothers who had received 
a single dose and two doses of ACS was statistically significant 
with respect to oxygen support in babies with RDS. There was 
no significant difference with respect to the need for surfactant 
administration and ventilator survival rate between babies 
of mothers who had received a single dose and two doses of 
ACS. The survival rate, in relation to the outcome of RDS, was 
significantly higher for babies of mothers who received two doses 
of antenatal steroids than the babies whose mothers received a 
single dose of antenatal steroids, whereas the incidence of RDS 
was significantly higher among preterm babies born to mothers 
who had received a single dose of ACS than the preterm babies 
born to mothers who had received two doses of antenatal steroids 
24 h apart (Table 4).
DISCUSSION
This study conducted at tertiary care teaching hospital in South 
India mainly investigated the effect of ACS on the occurrence 
of RDS and its outcome in preterm babies <34 weeks. We also 
compared neonatal outcomes of one dose versus two doses ACS 
in preterm infants. Preterm babies who have been exposed to 
repeated courses of ACS had a lower incidence of RDS than 
those who have been exposed to one course of ACS in few well-
designed randomized controlled studies[16-18] and in some other 
studies.[17,19] However, some studies[20,21] showed that there was 
no significant difference between repeated courses and a single 
course of ACS treatment. As such, there are no reports on the 
neonatal outcomes of one dose versus double dose of ACS and 
preterm infants. In this study, we analyzed the outcome between 
these groups, though the sample size was low in single dose group.
The study showed that there was a significant benefit of two 
doses of antenatal betamethasone over a single dose in threatened 
preterm deliveries with respect to RDS, need for mechanical 
ventilation, and mortality rate. The overall incidence of RDS in 
our study was 32.57%. This was slightly higher than the study 
by Lau et al. (17.6%) and Liggins et al. (9%).[7,22] The 1994 NIH 
consensus panel concluded that optimal benefit of ACS was seen 
at 24 h to 7 days of initiation of treatment. A high rate of occurrence 
of RDS in our study could be due to the short interval between 
initiation of therapy and preterm delivery. In this study, the 
requirement of mechanical ventilation in RDS was significantly 
associated with single dose steroid (72.5%) compared to double 
dose (12.4%) (p<0.001). A Cochrane review that summarizes the 
result of 10 randomized controlled trials says that more than one 
course of ACS reduces the risk of RDS.[18,23-25] In a retrospective 
cohort study by Vermillion and colleagues, rescue corticosteroid 
administration was significantly associated with a reduction in 
the frequency of RDS as well as mean days on the ventilator.[26]
Our study showed a significant survival benefit in babies 
with two doses of ACS. The reduced incidence of neonatal 
death with use of ACS in preterm was seen in many other 
studies.[14,27,28,] However, in the global networks, ACS trial (ACT), 
which was a multi-country trial to improve appropriate use of 
Table 3: Oxygen support in babies who received ACS
Babies with two doses of 
ACS (n=698)
Babies with one dose of 
ACS (n=57)
CPAP Mechanical ventilation CPAP Mech. ventilation
106 (15) 87 (12.4) 14 (27.4) 37 (72.5)
CPAP: Continuous positive airway pressure, ACS: Antenatal corticosteroids
Table 4: Association of various variables with the dose of ACS among mothers
Variables One dose (%) Two doses (%) p (Chi‑square value)
Oxygen support in babies with RDS
CPAP 14 (27.5) 106 (55) *0.001 (12.18)
Mechanical ventilation 37 (72.5) 87 (45)
Surfactant therapy in babies who had received ACS
Surfactant given 40 (78.4) 137 (70.9) 0.289 (1.12)
Surfactant not given 11 (21.6) 56 (29)
Outcome of RDS
Survival 35 (68.62) 168 (87) *0.0017 (9.79)
Death 16 (31.37) 25 (12.9)
Outcome of RDS in ventilated babies
Survival 21 (56.8) 62 (71.3) 0.116 (2.47)
Death 16 (43.2) 25 (28.7)
RDS in babies who had received ACS
RDS present 51 (100) 193 (27.6) *0.001 (113.27)
RDS absent 0 505 (72.3)
*p<0.05 (significant). RDS: Respiratory distress syndrome, ACS: Antenatal corticosteroids, CPAP: Continuous positive airway pressure
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ACS in low-resource settings in low-middle income countries, 
was associated with increased neonatal mortality and stillbirth 
in the overall population.[29] Although there were no significant 
difference in the rate of surfactant use and survival benefit of 
ventilated patients, the rate of surfactant use was high (78% vs. 
70.9%) and ventilator survival rate was low (56.8% vs. 71.4%) 
in one-dose ACS group than two-dose ACS group. This result is 
contrary to study by Wang et al,[30] which says that there was no 
significant differences in the rate of surfactant use and the rate of 
intubation between one dose and multiple doses of ACS. As per 
the report of Ikegami et al,[31] one dose antenatal betamethasone 
exposure improved lung compliance and decreased lung edema 
in a fetal lamb model. In our study, it showed that minimum two 
doses of ACS assist lung maturation during the fetal period than 
one dose of ACS.
The incidence of RDS was highest (60%) in 26–28 weeks 
babies. The beneficial effect of ACS at very early gestational 
age is more evident in mortality rate and neuromorbidity than in 
prevention of RDS.[18,21,23] They can improve the lung function 
once an adequate number of primary alveoli and lamellar bodies 
have started to appear which typically occur in the saccular phase 
of lung development. It is a well-proven fact that lung maturity 
improves as the gestational age increases and the incidence of 
RDS comes down. However, our study showed a slightly higher 
incidence of RDS (34%) in 32–34 weeks babies than 28–32 weeks 
babies (32%). The reason could be due to the small sample size 
of 32–34 weeks group (117) compared to 28–32 weeks group 
(627).[2]
The requirement of mechanical ventilation decreased as 
the gestational age increased. It was 100%, 57%, and 15%, 
respectively, in <28, 28–32, and 32–34 weeks gestational 
group. A similar finding was observed in a study by Colm 
et al.[32] Surfactant requirement also found to be decreased as the 
gestational age increased.
Our study also emphasizes the fact that a complete single 
course of ACS should be considered routine for all preterm 
deliveries[14,33,34] The optimal therapeutic window for delivery 
after corticosteroid administration was 2–7 days (ACOG2017).[35] 
Majority of studies suggest the same finding, but in a few studies, 
only 20–45% women delivered during that window period. In 
view of this, there must be ongoing development of strategies 
and quality improvement processes that encourage timely ACS 
administration to women at risk of preterm delivery.
This is a large observational study on ACS exposure with 
relatively good sample size and the only one that assessed the 
outcome between one-dose and two-dose ACS babies. However, 
some limitations were present in the study. The maternal risk 
factors and comorbid conditions, which are present at birth and 
associated with poor neonatal outcome such as pregnancy-induced 
hypertension (PIH), gestational diabetes mellitus, intrauterine 
growth restriction (IUGR), premature rupture of membranes, pre-
eclampsia, and placenta praevia were not included in the study 
which was considered as a major limitation of our study.[3] The 
timing of ACS administration in relation to gestational age at the 
administration and time from administration to delivery were 
not available. However, the inclusion of infants who received 
ACS outside the optimal window for administration, from more 
than 24 h to 7 days, would be expected to skew the results. 
Furthermore, data were not collected on whether fetal monitoring 
was undertaken or the length of maternal hospital admission 
before delivery.[36] The indication for preterm delivery was not 
available and may differ between groups.
CONCLUSION
Two doses of ACS 24 h apart can decrease the incidence of RDS, 
the need for mechanical ventilation, and increased survival rate 
of preterm. The neonatal outcomes were significantly different 
between one-dose ACS and two-dose ACS. This study emphasizes 
the need for developing quality improvement efforts to optimize 
appropriate and timely antenatal corticosteroid administration. To 
obtain more reliable and objective information, further research 
including randomized control trials is necessary.
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